Purpose One of the features in cancer development is the migration of cancer cells to form metastatic lesions. CYR61 protein promotes migration and the epithelial-mesenchymal transition in several cancer cell types. Evidence suggests that CYR61 and dexamethasone are relevant to colorectal cancer. However, relationships between them and colorectal cancer are still unclear. Understanding the molecular mechanism of colorectal cancer progression related with CYR61 and dexamethasone, which is widely used for combination chemotherapy, is necessary for improved therapy. Materials and Methods We used colorectal cancer cells, HCT116, co-treated with transforming growth factor β1 (TGF-β1) and dexamethasone to examine the inhibitory migration effect of dexamethasone by migratory assay. Alternatively, both migratory pathways, expression of AKT and ERK, and the target factor CYR61 was also tested by co-treatment with TGF-β1 and dexamethasone.
Results We report that dexamethasone significantly inhibited TGF-β1–induced cell migration, without affecting cell proliferation. Importantly, we observed that TGF-β1 promoted the epithelial- mesenchymal transition process and that dexamethasone co-treatment abolished this effect. ERK and AKT signaling pathways were found to mediate TGF-β1–induced migration, which was inhibited by dexamethasone. In addition, TGF-β1 treatment induced CYR61 expression whereas dexamethasone reduced it. These observations were compatible with the modulation of migration observed following treatment of HCT116 cells with human recombinant CYR61 and anti-CYR61 antibody. Our results also indicated that TGF-β1 enhanced collagen I and reduced matrix metalloproteinase 1 expression, which was reversed by dexamethasone treatment. Conclusion These findings suggested that dexamethasone inhibits AKT and ERK phosphorylation, leading to decreased CYR61 expression, which in turn blocks TGF-β1–induced migration.
Citations
Citations to this article as recorded by
Dexamethasone improves thymoma-associated myasthenia gravis via the AKT-mTOR pathway Yuxin Liu, Si Chen, Yan Wang, Zeyang Zhang, Hui Zhang, Ziyi Wang, Ziyou Tao, Jianyao Wang, Peng Zhang Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(2): 817. CrossRef
Global Proteomics Analysis of Lysophosphatidic Acid Signaling in PC-3 Human Prostate Cancer Cells: Role of CCN1 Pravita Balijepalli, Guihua Yue, Bhagwat Prasad, Kathryn E. Meier International Journal of Molecular Sciences.2024; 25(4): 2067. CrossRef
Useful Role of a New Generation of Dexamethasone, Vitamin E and Human Serum Albumin Microparticles in the Prevention of Excitotoxicity Injury in Retinal Ocular Diseases Javier Rodríguez Villanueva, Pedro de la Villa, Rocío Herrero-Vanrell, Irene Bravo-Osuna, Manuel Guzmán-Navarro Pharmaceutics.2024; 16(3): 406. CrossRef
Modulation of intestinal barrier function by glucocorticoids: Lessons from preclinical models Mireia Tena-Garitaonaindia, María Arredondo-Amador, Cristina Mascaraque, Maitane Asensio, Jose J.G. Marin, Olga Martínez-Augustin, Fermín Sánchez de Medina Pharmacological Research.2022; 177: 106056. CrossRef
ROS-responsive dexamethasone micelles normalize the tumor microenvironment enhancing hypericin in cancer photodynamic therapy Ruifeng Liang, Ka Hong Wong, Yan Yang, Yourong Duan, Meiwan Chen Biomaterials Science.2022; 10(4): 1018. CrossRef
Advantages and drawbacks of dexamethasone in glioblastoma multiforme Amir R. Afshari, Mehdi Sanati, Samaneh Aminyavari, Farzaneh Shakeri, Bahram Bibak, Zakieh Keshavarzi, Mohammad Soukhtanloo, Mohammad Jalili-Nik, Mohammad Montazami Sadeghi, Hamid Mollazadeh, Thomas P. Johnston, Amirhossein Sahebkar Critical Reviews in Oncology/Hematology.2022; : 103625. CrossRef
Dexamethasone Reduces Cell Adhesion and Migration of T47D Breast Cancer
Cell Line Leila Mohammadi, Bashir Mosayyebi , Mahsa Imani, Mohammad Rahmati Anti-Cancer Agents in Medicinal Chemistry.2022; 22(13): 2494. CrossRef
Live and let die: signaling AKTivation and UPRegulation dynamics in SARS-CoVs infection and cancer Mariana Suaya, Gonzalo Manuel Sánchez, Antonella Vila, Analía Amante, María Cotarelo, Mercedes García Carrillo, Matías Blaustein Cell Death & Disease.2022;[Epub] CrossRef
Cyr61 from adipose‐derived stem cells promotes colorectal cancer metastasis and vasculogenic mimicry formation via integrin αVβ5 Zhenxing Liang, Huashan Liu, Yunfeng Zhang, Li Xiong, Ziwei Zeng, Xiaowen He, Fengwei Wang, Xianrui Wu, Ping Lan Molecular Oncology.2021; 15(12): 3447. CrossRef
Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer Alicia M. Hidalgo-Estévez, Konstantinos Stamatakis, Marta Jiménez-Martínez, Ricardo López-Pérez, Manuel Fresno Frontiers in Pharmacology.2020;[Epub] CrossRef
Overexpression of lncRNA NLIPMT Inhibits Colorectal Cancer Cell Migration and Invasion by Downregulating TGF-β1
Yongkang An, Shuangxi Zhang, Jing Zhang, Qing Yin, Haitao Han, Fang Wu, Xiangan Zhang Cancer Management and Research.2020; Volume 12: 6045. CrossRef
Transforming Growth Factor Beta 2 Inhibits Growth and Proliferation Potential of Smad4 and p53 Mutated Human Colon Adenocarcinoma Cells Ramamoorthi Ganesan, Nageswaran Sivalingam Pathology & Oncology Research.2019; 25(2): 819. CrossRef
Downregulation of miR-142-5p promotes tumor metastasis through directly regulating CYR61 expression in gastric cancer Jing Yan, Bing Yang, Shuye Lin, Rui Xing, Youyong Lu Gastric Cancer.2019; 22(2): 302. CrossRef
Role of the transforming growth factor‐β signaling pathway in the pathogenesis of colorectal cancer Atena Soleimani, Mehran Pashirzad, Amir Avan, Gordon A. Ferns, Majid Khazaei, Seyed Mahdi Hassanian Journal of Cellular Biochemistry.2019; 120(6): 8899. CrossRef
Tanshinone IIA reverses EGF‑ and TGF‑β1‑mediated epithelial‑mesenchymal transition in HepG2 cells via the PI3K/Akt/ERK signaling pathway Longkai Zhang, Weibin Lin, Xiaodan Chen, Gang Wei, Hailong Zhu, Shangping Xing Oncology Letters.2019;[Epub] CrossRef
Dexamethasone and lenvatinib inhibit migration and invasion of non‑small cell lung cancer by regulating EKR/AKT and VEGF signal pathways Daye Zhang, Yongxiang Zhang, Zeyuan Cai, Ying Tu, Zhansong Hu Experimental and Therapeutic Medicine.2019;[Epub] CrossRef
Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways Yusuke Tomita, Kazuhiko Kurozumi, Ji Young Yoo, Kentaro Fujii, Tomotsugu Ichikawa, Yuji Matsumoto, Atsuhito Uneda, Yasuhiko Hattori, Toshihiko Shimizu, Yoshihiro Otani, Tetsuo Oka, Balveen Kaur, Isao Date Molecular Cancer Therapeutics.2019; 18(8): 1418. CrossRef
Glucocorticoids indirectly decrease colon cancer cell proliferation and invasion via effects on cancer-associated fibroblasts Zuzanna Drebert, Elly De Vlieghere, Jolien Bridelance, Olivier De Wever, Karolien De Bosscher, Marc Bracke, Ilse M. Beck Experimental Cell Research.2018; 362(2): 332. CrossRef
UBXN2A enhances CHIP‐mediated proteasomal degradation of oncoprotein mortalin‐2 in cancer cells Sanam Sane, Andre Hafner, Rekha Srinivasan, Daniall Masood, John l. Slunecka, Collin J. Noldner, Alex D. Hanson, Taylor Kruisselbrink, Xuejun Wang, Yiyang Wang, Jun Yin, Khosrow Rezvani Molecular Oncology.2018; 12(10): 1753. CrossRef
Targeting cysteine‑rich angiogenic inducer‑61 by antibody immunotherapy suppresses growth and migration of non‑small cell lung cancer Xinpeng Li, Naxin Yuan, Lingdan Lin, Lixia Yin, Yiqing Qu Experimental and Therapeutic Medicine.2018;[Epub] CrossRef
Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy Qi Zhang, Bo Zhu, Yongsheng Li Frontiers in Immunology.2017;[Epub] CrossRef
Crosstalk between Smad2/3 and specific isoforms of ERK in TGF‐β1‐induced TIMP‐3 expression in rat chondrocytes Yanhui Zhu, Jianhua Gu, Tong Zhu, Chen Jin, Xiaopeng Hu, Xiang Wang Journal of Cellular and Molecular Medicine.2017; 21(9): 1781. CrossRef
Ginsenoside Rg1 Attenuates Cigarette Smoke-Induced Pulmonary Epithelial-Mesenchymal Transition via Inhibition of the TGF-β1/Smad Pathway Sibin Guan, Weiguo Xu, Fengfeng Han, Wen Gu, Lin Song, Wenjing Ye, Qian Liu, Xuejun Guo BioMed Research International.2017; 2017: 1. CrossRef
TGF-β1/PTEN/PI3K signaling plays a critical role in the anti-proliferation effect of tetrandrine in human colon cancer cells Qian-Zhao Chen, Yang Li, Ying Shao, Yu-Hua Zeng, Wen-Yan Ren, Rong-Xing Liu, Lin-Yun Zhou, Xue-Lian Hu, Ming Huang, Fang He, Wen-Juan Sun, Ke Wu, Bai-Cheng He International Journal of Oncology.2017; 50(3): 1011. CrossRef
C1QBP is upregulated in colon cancer and binds to apolipoprotein A-I Kun Kim, Min-Jeong Kim, Kyung-Hee Kim, Sun-A Ahn, Jong Heon Kim, Jae Youl Cho, Seung-Gu Yeo Experimental and Therapeutic Medicine.2017; 13(5): 2493. CrossRef
Chimeric antibody targeting SRPK-1 in the treatment of non-small cell lung cancer by inhibiting growth, migration and invasion Fan Wu, Jie Li, Xin Du, Weisan Zhang, Ping Lei, Qiang Zhang Molecular Medicine Reports.2017; 16(2): 2121. CrossRef
MicroRNA target for MACC1 and CYR61 to inhibit tumor growth in mice with colorectal cancer Guiqi Wang, Jingfeng Gu, Yingchao Gao Tumor Biology.2016; 37(10): 13983. CrossRef
Systematic review of the old and new concepts in the epithelial-mesenchymal transition of colorectal cancer Simona Gurzu, Camelia Silveanu, Annamaria Fetyko, Vlad Butiurca, Zsolt Kovacs, Ioan Jung World Journal of Gastroenterology.2016; 22(30): 6764. CrossRef
Pazopanib is a potent multitargeted tyrosine kinase inhibitor that has been shown to have good efficacy in patients with renal cell carcinoma. A previous phase II trial demonstrated that short-term pazopanib administration was generally well tolerated and showed antitumor activity in patients with early-stage non-small cell lung cancer. Herein, we report on the case of a 66-year-old man with simultaneous metastatic squamous cell carcinoma of the lung and renal cell carcinoma who was treated with pazopanib. The patient showed an unexpected partial response and experienced a 10-month progression-free survival without significant toxicity. To the best of the authors’ knowledge, this is the first report of pazopanib treatment in a non-small cell lung cancer patient in Korea. The results in this patient suggest that pazopanib may be a valid treatment option for advanced non-small cell lung cancer.